A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

At 2-year follow-up, a septal occluder device was deemed safe and effective for transcatheter closure of atrial septal defects, according to new data published in Circulation: Cardiovascular ...

The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, an institute of national importance, has developed a nickel-titanium alloy based occlusion device ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market for Heart Defect Closure Devices - 2016 (Forecasted to 2022) - MedCore" report to their offering. As of ...

NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...

TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...

Rates of nonrelapse mortality and 3-year overall survival were similar between patients 55 to 64 years old and patients 65 years or older who underwent transplantation. Patients who are older and have ...

Expert Rev Cardiovasc Ther. 2007;5(6):1135-1146. Diagnosing a secundum ASD is more often than not incidental because the defect normally causes symptoms late in adult life. Echocardiography and MRI ...

February 7, 2008 (Chicago, IL) - Doctors and regulators concerned about the spike in off-label patent foramen ovale (PFO) closure procedures now have some numbers to fall back on. A research letter ...

LONDON--(BUSINESS WIRE)--The global heart defect closure devices market research report by Technavio predicts the market to post a CAGR of more than 29% during the period 2019-2023. A key driver for ...